Emily Field, head of European pharmaceuticals research at Barclays, weighs in on rising competition in the global obesity ...

Next-generation obesity drugs will work differently from Ozempic and Wegovy — aiming to deliver greater weight loss with ...

Zillow economists have developed an economic model called Zillow’s Market Heat Index, which measures the competitiveness of housing markets across the U.S. This model analyzes factors such as ...

Jan. 27, 2025 — A study shows that patients with obesity and fatty liver-related cirrhosis who had bariatric (weight-loss) surgery significantly lowered their future ... Signposting Children to ...

Lilly is looking to take market share from rival Novo Nordisk in the obesity market after a head-to-head trial showed Zepbound helped patients lose more weight than Wegovy. The market for these ...

All hands on deck' at Lilly as competitors come for obesity market Lilly has invested billions into manufacturing capabilities to support the launch of obesity drug Zepbound and other phase 3 ...

Furthermore, considering the substantial investment made by big pharma, the obesity market is highly capital intensive, a great challenge for emerging players, contends the firm. Such challenges ...

The September 2024 Project Gigabit Open Market Review data was published on 30th January 2025 and we can now announce that our maps site has integrated the 30 million UPRN covering England and Wales ...

It's just—this market is quite different." Large study of Novo, Lilly weight loss drugs shows decrease in risk of Alzheimer's The question of just how to reckon with the scope of the obesity ...

Perceptual maps are the only way to understand what your position is in the market and how the market views you vs. your competitors. In fact, if you don't have a perceptual map, in essence you're ...

Obesity care sales increased by 57%, driven by significant growth in both North America and international operations. Novo Nordisk AS (NYSE:NVO) maintained its leadership in the GLP-1 market ...